In 2017,Odingo, Joshua; Bailey, Mai A.; Files, Megan; Early, Julie V.; Alling, Torey; Dennison, Devon; Bowman, Julie; Dalai, Suryakanta; Kumar, Naresh; Cramer, Jeffrey; Masquelin, Thierry; Hipskind, Philip A.; Parish, Tanya published 《In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis》.ACS Omega published the findings.Safety of Methyl 5-bromopicolinate The information in the text is summarized as follows:
Nitazoxanide has antiparasitic and antibiotic activities including activity against Mycobacterium tuberculosis. We prepared and evaluated a set of its analogs to determine the structure-activity relationship, and identified several amide- and urea-based analogs with low micromolar activity against M. tuberculosis in vitro. Pharmacokinetics in the rat suggested a path forward to obtain bioavailable compounds The series had a good microbiol. profile with bactericidal activity in vitro against replicating and nonreplicating M. tuberculosis. Analogs had limited activity against other Gram-pos. bacteria but no activity against Gram-neg. bacteria. Our studies identified the key liability in this series as cytotoxicity. Future work concentrating on identifying the target(s) could assist in removing activity against eukaryotic cells. After reading the article, we found that the author used Methyl 5-bromopicolinate(cas: 29682-15-3Safety of Methyl 5-bromopicolinate)
Methyl 5-bromopicolinate(cas: 29682-15-3) belongs to pyridine. In industry and in the lab, pyridine is used as a reaction solvent, particularly when its basicity is useful, and as a starting material for synthesizing some herbicides, fungicides, and antiseptics.Safety of Methyl 5-bromopicolinate